Percutaneous trans-hepatic local sclerotherapy of symptomatic giant liver hemangioma

Abstract

Author(s): Rafid Abdulrazzaq Abdulazeez*, Rana T. Mehsen and Zaid Hadi Kadhim

Background: The hepatic haemangioma is a common benign tumour of the liver that is diagnosed incidentally by radiology. Different treatment options are available in treatment of hepatic haemangioma with different advantages and disadvantages. Aim of study: To evaluate the role of percutaneous sclerotherapy with bleomycin in the treatment of giant hepatic haemangioma.

Patients and methods: A clinical prospective follow up study carried out in the Ghazi Al-Hariry Teaching Hospital/ Medical City Complex in Baghdad City-Iraq through the period of six months 1st of December, 2021 to 31st of May, 2022 on convenient sample of fifteen patients with symptomatic liver haemangioma. The diagnosis of symptomatic liver haemangioma was done by Radiologist by computerized tomography scan. The procedure was performed injecting 60 IU bleomycin under ultrasound provision.

Results: There was a highly significant decline in Craniocaudally diameter of haemangioma 6 months after injection (p<0.001). A highly significant decline was observed in transverse diameter of haemangioma 6 months after injection (p<0.001). There was a highly significant decline in anteroposterior diameter of haemangioma 6 months after injection (p<0.001). Consequently, the volume and size of haemangioma were significantly declined 6 months after injection (p<0.001). Conclusions: The percutaneous sclerotherapy with bleomycin is new method in the treatment of giant hepatic haemangioma.

Share this article